NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.
|Bank Name||NanoVibronix, Inc.|
|Chairman||Dr. Patrick Soon-Shiong FRCS|
|CEO||Dr. Patrick Soon-Shiong FRCS|